LAKE FOREST, Calif., September 22, 2022 /PRNewswire/ — BIOLASEInc. (NASDAQ: BIOL), the world leader in dental lasers, today announced that it has engaged Providence Film Group, a subsidiary of Valiant Eagle, Inc. (OTC: PSRU) to produce a docuseries titled “Talk Dental to Me.”

BIOLASE Logo (PRNewsfoto/BIOLASE, Inc.)

As part of this groundbreaking deal, Providence Film Group will produce a one-of-a-kind branded docuseries. Unscripted Television Veteran Debbie Levin is set to direct, with Xavier Mitchell to executive products.

The docuseries will explore the painful, if hysterical, history of dentistry as well as the evolution and revolution of modern dental technologies, including lasers.

From dental worms and shell implants to barbers performing tooth extractions, we’ve come a long way from the barbaric procedures and excruciating pain once commonly associated with dental visits. However, even with years of progress, the one thing that hasn’t changed is the fear many of us still feel when we hear the words “Please open wider!”

Revolutionary changes are underway in dentistry and BIOLASE has led the way by developing innovative technology to provide superior, user-friendly clinical results compared to those achieved with traditional instruments.

“I consider BIOLASE to be the Tesla of the dental industry,” said Xavier Mitchell, Executive producer. “Its technology is unparalleled and will revolutionize the industry.”

Waterlase dental lasers are a worldwide phenomenon. Benefits of Waterlase lasers include less pain, less bleeding and swelling, as well as reduced anxiety, shorter procedures, and little or no anesthesia required. Dental lasers also reduce the need for traditional tools such as injections, drills and scalpels.

“We are thrilled to partner with Providence Film Group and Valiant Eagle to help educate the general population about laser dentistry,” said John Beaver, Chairman and CEO of BIOLASE. “We believe our technology is superior to all current industry methodologies. As we continue to rapidly gain market share, we look forward to ushering in a new era of dental innovation where laser dentistry will become the new standard of care.”


BIOLASE is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. BIOLASE products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE’s proprietary laser products incorporate approximately 302 patented and 31 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE’s innovative products offer advanced technology at competitive prices to deliver superior results for dentists and patients. BIOLASE’s main products are dental laser systems that perform a wide range of dental procedures, including cosmetic and complex surgical applications. From 1998 to December 31, 2021, BIOLASE has sold more than 43,300 laser systems in more than 80 countries around the world. The laser products under development address BIOLASE’s core dental market and other adjacent medical and consumer applications.

For updates and information on Waterlase iPlus®, Waterlase Express™ and laser dentistry, find BIOLASE online at, Facebook at, Twitter at at and LinkedIn at

BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.

Caution Regarding Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements regarding expected revenues and revenue growth of BIOLASE and its beliefs about their financial resources. Forward-looking statements can be identified by the use of words such as “may”, “could”, “will”, “intend”, “should”, “could”, “may”, “should”, “continue”, “expect”, “believe”, “anticipate”, “estimate”, “predict”, “prospects”, “potential”, “plan”, “seek” and similar expressions and variations or the negatives of these terms or other comparable terms terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE’s current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE’s current expectations based on a number of factors. These factors include, but are not limited to, the coronavirus (COVID-19) and the effects of the outbreak and actions taken with respect thereto, adverse changes in general economic and market conditions, competitive factors, including , but not limited to, pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing growth of the business and the other risks and uncertainties which are described in the “Risk Factors” section of BIOLASE’s most recent annual report filed on Form 10-K filed with the Securities and Exchange Commission. Except as required by law, BIOLASE assumes no responsibility to revise or update forward-looking statements.

For more information, please contact:

Michel Polyviou / Todd Kehrli
(732) 933-2754
[email protected] / [email protected]



View original content to download multimedia: .html



About Author

Comments are closed.